ReviewFrontiers in ophthalmology2026
Natural compounds as potential countermeasures for spaceflight-associated neuro-ocular syndrome.
Review in Frontiers in ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spaceflight-Associated Neuro-Ocular Syndrome (SANS) is a complex and multifactorial condition most commonly observed following long-duration spaceflight. Clinical findings of SANS include optic disc edema, retinal nerve fiber layer swelling, globe flattening, chorioretinal folds, and hyperopic refractive shifts. As human space exploration extends toward prolonged missions such as Artemis and Mars expeditions, SANS represents a significant risk to astronaut health and mission success. Although headward fluid shifts, elevated intracranial pressure, venous outflow congestion, and lymphatic dysfunction have been implicated in SANS pathophysiology, no single unifying mechanism or universally effective countermeasure has been identified. Emerging evidence suggests that oxidative stress from galactic cosmic radiation, endothelial dysfunction, inflammation, mitochondrial injury, altered angiogenesis, and disruptions in one-carbon metabolism contribute meaningfully to SANS development. This review summarizes the clinical manifestations and proposed mechanisms underlying SANS and examines naturally occurring compounds with high therapeutic indices that target these pathways. Specifically, we review bilberry anthocyanins with French maritime pine bark extract, Ginkgo biloba extract, saffron/crocin, curcumin, coenzyme Q10, resveratrol, vitamin E, and B vitamins as potential supplemental approaches, highlighting their mechanisms of action and therapeutic efficacy when targeting terrestrial ocular diseases. While direct studies in spaceflight environments remain limited, these compounds demonstrate antioxidant, anti-inflammatory, neuroprotective, vasoregulatory, and metabolic effects relevant to SANS. Collectively, they represent promising adjunctive candidates within a multimodal preventative strategy aimed at mitigating SANS risk during long-duration spaceflight.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.